Skip to content
AnalystLens

BridgeBio Pharma Quarterly Report for Q1 Ended Mar 31, 2026

Filing Date
Filed May 7, 2026
Period End
March 31, 2026
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · Sep ’23Sep ’23
  4. Material agreement8-K · Jul ’25Jul ’25

Summary

Summary of the 10-Q filed May 7, 2026. Cited figures are marked; the original filing is the authoritative source.

BridgeBio Pharma, Inc. (BridgeBio) reported a net loss of $166.6 milliona for the three months ended March 31, 2026, compared with $169.6 million in the same period of 2025.

Total revenues, net were $194.5 millionb, up from $116.6 million, driven by net product revenue of $180.6 million (versus $36.7 million), while license and services revenue fell to $4.4 million from $79.7 million, which the filing attributes mainly to $75.0 million of milestone revenue recognized in 2025 following Beyonttra's EU approval. Royalty revenue rose to $9.5 million. Operating expenses increased, with selling, general and administrative expenses at $163.9 million (up from $106.4 million) and research and development at $126.6 million (up from $111.4 million).

Net cash used in operating activities was $197.3 millionc. Balance sheet activity was dominated by financing. In January 2026 the company issued $632.5 million of 0.75% convertible senior notes due 2033 and used $82.5 million of proceeds to repurchase 1,081,825 shares of common stock.

As of March 31, 2026, cash, cash equivalents and marketable securities totaled $940.2 milliond, and the company reported stockholders' deficit of $2.27 billion, with the 2027 Notes classified as current. Management states that existing cash and marketable securities and Attruby revenue are expected to fund operations for at least the next 12 months.

On May 6, 2026, the Board approved a stock repurchase program of up to $500.0 million. The filing also notes that the company submitted a New Drug Application to the FDA for oral BBP-418 for LGMD2I/R9 on March 30, 2026, and that the 2027 and 2031 Notes became convertible for a limited period from April 1, 2026 through June 30, 2026 after a conversion condition was met.

Key Highlights

  1. Net product revenue of $180.6 million for Q1 2026, up from $36.7 million in Q1 2025, with total revenues, net of $194.5 million versus $116.6 million.
  2. Net loss of $166.6 million ($0.84 per share attributable to common stockholders) versus $169.6 million a year earlier; net cash used in operating activities was $197.3 million.
  3. License and services revenue declined to $4.4 million from $79.7 million, reflecting $75.0 million of Bayer milestone revenue recognized in Q1 2025.
  4. Issued $632.5 million of 0.75% convertible senior notes due 2033 in January 2026, with net proceeds of approximately $619.3 million.
  5. Cash, cash equivalents and marketable securities of $940.2 million at March 31, 2026, against total debt of $2.5 billion in convertible notes and $892.7 million of deferred royalty obligations.
  6. Board approved a stock repurchase program of up to $500.0 million on May 6, 2026.
  7. Submitted a New Drug Application to the FDA for oral BBP-418 for LGMD2I/R9 on March 30, 2026.

Follow one dollar

For each $1.00 of revenue in Q1 FY2026, BridgeBio Pharma lost $0.84.

  1. Revenue$194.5M100.0%
  2. Cost of revenue−$9.9M5.1%
  3. Gross profit$184.6M94.9%
  4. Operating costs−$290.5M149.4%
  5. Operating income−$106.0M54.5%
  6. Interest, other & tax−$58.1M29.9%
  7. Net income−$164.0M84.3%
Computed from 10-QQ1 FY2026filed May 7, 2026Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q1 FY2026 against Q1 FY2025

Line itemQ1 FY2026Q1 FY2025Change
Revenue$194.51M$116.63M+66.8%
Cost of Revenue$9.94M$2.64M+276.6%
Gross Profit$184.58M$113.99M+61.9%
R&D Expenses$126.64M$111.43M+13.6%
SG&A Expenses$163.90M$106.36M+54.1%
Operating Expenses$300.47M$221.00M+36.0%
Operating Income-$105.96M-$104.37M−1.5%
Net Income-$164.04M-$167.42M+2.0%
EPS (Basic)$-0.84$-0.88+4.5%
EPS (Diluted)$-0.84$-0.88+4.5%
Shares Outstanding (Basic)194.79M190.15M+2.4%
Shares Outstanding (Diluted)194.79M190.15M+2.4%

Frequently Asked Questions

  1. Is BridgeBio's Attruby revenue growing?

    Net product revenue was $180.6 million for the three months ended March 31, 2026, compared with $36.7 million in the same period of 2025. The filing states that net product revenue from Attruby increased, and it attributes royalty revenue growth to net product sales of Beyonttra in the EU and Japan.

  2. Why did license and services revenue fall so sharply?

    License and services revenue was $4.4 million versus $79.7 million a year earlier. The filing attributes the decrease primarily to recognition of $75.0 million of license and services revenue in 2025 for milestone achievements following the approval of Beyonttra in the EU.

  3. How is BridgeBio funding its operations and debt obligations?

    The company cites cash, cash equivalents and marketable securities of $940.2 million and expects these, together with Attruby product revenue, to fund operations for at least the next 12 months. Debt includes the 2033, 2031, 2029 and 2027 convertible notes; the 2027 Notes mature March 15, 2027 and are classified as current. The company intends to use remaining 2033 Note proceeds to settle future conversion obligations or repay a portion of the 2027 Notes.

  4. What do the 2027 and 2031 convertible notes mean for shareholders?

    The filing states the 2027 and 2031 Notes became convertible for a limited period from April 1, 2026 through June 30, 2026 because an early conversion condition based on the stock price was satisfied. The company may settle conversions in cash, shares or a combination, and a cash settlement could reduce liquidity.

  5. What is the status of the company's stockholders' equity?

    Total stockholders' deficit was $2.27 billion at March 31, 2026, compared with $2.08 billion at December 31, 2025. The company has an accumulated deficit of $4.0 billion, and management expects to continue incurring operating and net losses over the next several years.